Nutropin AQ NuSpin to be discontinued
On Dec. 31, 2024, Genentech will discontinue manufacturing Nutropin® AQ® (somatropin) NuSpin® in the United States. As a result, most UnitedHealthcare plans will no longer cover Nutropin AQ, effective Jan. 1, 2025.
Preferred covered alternative
To help ensure your patients continue to have access to growth hormone therapy, please see these preferred alternative growth hormones by plan:
| Plan | Preferred alternative growth hormone1 |
|---|---|
| UnitedHealthcare commercial plans | Norditropin® and Omnitrope® |
| UnitedHealthcare Individual Exchange plans2,3 | Omnitrope |
| UnitedHealthcare Community Plan | Medicaid Core Prescription Drug List: 4 Norditropin and Omnitrope View drug lists by state for preferred medication information. Prescription drug lists may vary by state. |
| UnitedHealthcare® Medicare Advantage and Part D plans | Genotropin® |
What you need to do
Consider prescribing your affected patient(s) a new medication before the change takes effect.
To access covered alternatives information for your patients, use PreCheck MyScript®.
Questions? We're here to help
Connect with us through chat 24/7 in the UnitedHealthcare Provider Portal. For additional contact information, visit our Contact us page.
1Prior authorization and/or quantity limits may apply
2Also referred to as UnitedHealthcare Individual and Family ACA Marketplace plans
3Nutropin AQ will be non-formulary as of Jan. 1, 2025, for Individual Exchange plans
4Nutropin AQ will be non-preferred as of Jan. 1, 2025, for the Medicaid Core Prescription Drug List
PCA-1-24-02191-Clinical-NN_07232024
